Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Codexis, Inc.NASDAQ: CDXS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $1.43M fell 40.0% year over year, behind the -29.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 35.1% from the prior quarter. Over 3 fiscal years it compounded at -12.8% a year.

Context

  • Stock-based compensation amounted to 13.7% of revenue in FY2025, down 8.4 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -40.0% toward the trailing-twelve-month pace of -29.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.43M-35.1% QoQ
Last fiscal yearDec 2025
$9.62M-26.5% YoY
LTMMar 2026
$8.67M-29.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.0%——
1 year-26.5%——
3-year CAGR-12.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.62M USD
Year-over-year change
-26.5%
4-year CAGR
-4.5%

Stock-Based Compensation vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -29.5% is the 6th highest of 10, against a peer median of -24.7%.
  • Stock-based compensation amounts to 11.1% of revenue for CDXS, versus a peer median of 75.1%.
CDXS Competitors
Stock-Based Compensation for CDXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CCCCC4 Therapeutics, Inc.LTM Mar 2026$16.26M USD-43.8%-14.0%46.7%
OABIOmniAb, Inc.LTM Mar 2026$15.02M USD-24.7%-4.8%52.0%
IVVDInvivyd, Inc.LTM Mar 2026$11.51M USD-33.2%-18.7%20.6%
CDXSCodexis, Inc.LTM Mar 2026$8.67M USD-29.5%-12.8%11.1%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$7.48M USD-39.0%-34.0%21.6%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$6.67M USD-45.2%-9.2%210.3%
TARAProtara Therapeutics, Inc.LTM Mar 2026$4.36M USD+16.7%-17.0%—
IPHAInnate Pharma S.A.FY2025€4.26M EUR+7.9%+0.1%152.7%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.9M USD-7.5%-5.6%98.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$2.4M USD+50.7%-39.5%123.1%
Peer median (excluding CDXS) —-24.7%-14.0%75.1%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Depreciation & Amortization5.95M10.25M9.92M4.95M5.25M
Deferred Income Tax(2.89M)0000
Stock-Based Compensation11.59M14.53M9.97M13.09M9.62M
Change in Working Capital(7.62M)21.57M(18.22M)(12.02M)6.42M
Accounts Receivables(15.57M)(3.23M)20.25M1.25M8.51M
Inventory(196K)(869K)(656K)886K(19K)
Accounts Payables268K207K2.29M(2.57M)(1.29M)
Other Working Capital7.88M25.46M(40.1M)(11.59M)(784K)
Other Non-Cash Items(19K)(1.48M)21.93M9.85M3.31M
Operating Cash Flow(14.27M)11.28M(52.64M)(49.41M)(19.38M)
Capital Expenditures(13.83M)(8.31M)(4.42M)(4.31M)(4.47M)
Acquisitions (Net)36K29K751K87K5K
Purchases of Investments(7.63M)(5.3M)(1.19M)(90.24M)(57.16M)
Sales of Investments(36K)(29K)440K37.47M85.13M
Other Investing Activities36K29K(440K)00
Investing Cash Flow(21.42M)(13.58M)(4.86M)(56.98M)23.5M
Debt Repayment00029.52M9.89M
Common Stock Issued4.97M913K8.65M31.32M18.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.21M)(1.49M)(485K)(318K)0
Financing Cash Flow3.77M(575K)8.17M60.52M27.93M
Effect of Forex Changes00000
Net Change in Cash(31.92M)(2.87M)(49.33M)(45.87M)32.05M
Free Cash Flow(28.1M)2.98M(57.06M)(53.72M)(23.85M)

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.